Good Clinical Approach: Delphi Consensus for the Use of Betahistine in Menière’s Disease
Table 1
Results of the Consensus Conference on the use and dosage of betahistine during the intercritical phase of MD. 1 = absolutely disagree, 2 = disagree, 3 = agree, 4 = more than agree, and 5 = absolutely agree. Consensus was reached when the sum of items 1 and 2 or 3, 4, and 5 reached 66%. Asterisk explanations: Negative consensus, No consensus, and Positive consensus.
1
2
3
4
5
In the inter-critical phase therapy, referred to the vertigo in the Menière’s disease, do you think that betahistine:
1. Is useful
8%
5%
41%
23%
23%
13
87
2. Is useful only when associated to other therapies
8%
66%
12%
12%
2%
74
26
3. It’s the first-choice drug
3%
26%
19%
26%
26%
29
71
4. Shows poor efficacy
49%
45%
2%
4%
0%
94
6
If you use Betahistine for prophylaxis what is the dosage that you use: